Keywords
RASS system
Renal Yang deficiency hypertension
Submitted : 2025-06-08
Accepted : 2025-06-23
Published : 2025-07-08
Abstract
Objective: This study explores the mechanism and clinical efficacy of combined external therapies of traditional Chinese medicine (such as moxibustion, acupoint application, etc.) in intervening renal Yang deficiency hypertension through regulating the renin-angiotensin-aldosterone system (RASS). Methods: Sixty-one patients with renal Yang deficiency hypertension admitted to the hospital were selected as the study subjects. They were divided into a Western medicine combined with external therapies of traditional Chinese medicine group (n=30) and a conventional Western medicine treatment group (n=31) based on a random number table method. The enrollment information, blood pressure changes, and differences in aldosterone, angiotensin II, and renin activity during follow-up were compared between the two groups. Results: There were no statistically significant differences in gender, past history, pre-study medication, hypertension grading, aldosterone, angiotensin II, renin activity levels, and blood pressure between the two groups at baseline (P > 0.05). Aldosterone, angiotensin II, and renin activity levels were significantly reduced in both groups after treatment compared to pre-treatment levels. Moreover, the aldosterone, angiotensin II, and renin activity levels in the Western medicine combined with external therapies of traditional Chinese medicine group were significantly lower than those in the conventional Western medicine treatment group, with statistically significant differences (P < 0.05). Conclusion: Western medicine combined with external therapies of traditional Chinese medicine may regulate the RASS system through multiple targets, restoring renal Yang Qi transformation function and providing a new strategy for the integrated treatment of renal Yang deficiency hypertension with Chinese and Western medicine.
References
Huang Z, 2022, Association Between Blood Lead Level With High Blood Pressure in US (NHANES 1999–2018). Front Public Health, 10: 836357.
Bader M, Steckelings U, Alenina N, et al., 2024, Alternative Renin–Angiotensin System. Hypertension, 81(5): 964–976.
Al-Anazi AF, Gul R, Al-Harbi FT, et al., 2023, Home Versus Clinic Blood Pressure Monitoring: Evaluating Applicability in Hypertension Management via Telemedicine. Diagnostics (Basel), 13(16): 2686.
Xie M, Tang T, Liang H, 2023, Efficacy of Single-Pill Combination in Uncontrolled Essential Hypertension: A Systematic Review and Network Meta-Analysis. Clin Cardiol, 46(8): 886–898.
Yu X, Qin W, Cai H, et al., 2024, Analyzing the Molecular Mechanism of Xuefuzhuyu Decoction in the Treatment of Pulmonary Hypertension With Network Pharmacology and Bioinformatics and Verifying Molecular Docking. Comput Biol Med, 169: 107863.
Huang S, Cai S, Ling L, et al., 2024, Investigating the Molecular Mechanism of Traditional Chinese Medicine for the Treatment of Placental Syndromes by Influencing Inflammatory Cytokines Using the Mendelian Randomization and Molecular Docking Technology. Front Endocrinol (Lausanne), 14: 1290766.
Xue B, Zhang Y, Johnson A, 2020, Interactions of the Brain Renin–Angiotensin–System (RAS) and Inflammation in the Sensitization of Hypertension. Front Neurosci, 14: 650.
Li Z, Wu M, Liu D, et al., 2021, Pingyang Jiangya Fang Pretreatment Reduces the Blood Pressure of Spontaneously Hypertensive Rats With Liver–Yang Hyperactivity Syndrome via ROS/Akt Oxidative Stress Pathway. Ann Palliat Med, 10(2): 1904–1919.
Lai X, Dong Z, Wu S, et al., 2022, Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. Circ Cardiovasc Qual Outcomes, 15(3): e007923.
Li D, Tang W, Wang Y, et al., 2023, An Overview of Traditional Chinese Medicine Affecting Gut Microbiota in Obesity. Front Endocrinol (Lausanne), 14: 1149751.